Osl asx

OncoSil Medical Limited. OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide, osl asx. About the osl asx. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy.

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech. Show more Markets link Markets.

Osl asx

At OncoSil Medical, we are committed to making a positive change through the dedication and compassion of our team. This is why it is important that you get to know the people behind the logo. At OncoSil Medical we have a policy of continuous disclosure. We keep shareholders informed through ASX announcements, the company website, regular newsletters and our annual report. We encourage our shareholders to attend and participate at our annual general meetings. Until recently, he was the Group Chief Operating Officer at Telix Pharmaceuticals ASX:TLX a global biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Currently, Dr Liberatore is a Strategic Advisor to GlyTherix Ltd, an Australian immuno-oncology company specializing in developing antibody radiopharmaceuticals for solid tumours. In addition, Renzo led the development and set-up of the very first Lu, Y and Sr isotopes radiochemical processes in the industry in the early s. He is responsible for leading the clinical research program on novel provide global clinical evidence for the company. More specifically, Henk has held senior leadership positions in the development of clinical programs for brachytherapy over the past 10 years. Chief Financial Officer Christian has extensive experience with listed and private companies includes corporate secretarial, accounting and general management through The CFO Solution and previous roles. Dr Jon Bell trained in surgery and clinical radiology before completing higher sub-specialty training in Interventional Radiology. He is an internationally recognised expert in Interventional Oncology and his primary research interest is in liver directed brachytherapy. Nigel is also a specialist in corporate turnaround.

Mar 06

Morningstar Investor users sign in here. Skip to Content. Market Centre. United States. Market Report.

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders. Our Board. Corporate governance. Media centre.

Osl asx

OncoSil Medical Ltd is an Australia-based medical device company seeking to advance radiation for cancer patients. The Company is focused on the development and commercialization of its lead product candidate, OncoSil localized radiation therapy, for the treatment of pancreatic and distal cholangiocarcinoma. OncoSil is a single-use brachytherapy device that has received breakthrough device designation in the European Union, the United Kingdom, and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy. OncoSil comprises phosphorous microparticles suspended in a specially formulated diluent.

Enervate in sentence

Roundup of Global market movements. David has over 25 years at board and senior executive level, most recently as Global Head of Marketing for Sirtex Medical Limited. For Asset Managers. Search the FT Search. OncoSil Medical Limited. Nov Listed Company Services. Read more. He is an internationally recognised expert in Interventional Oncology and his primary research interest is in liver directed brachytherapy. He graduated in medicine from the University of Cambridge, United Kingdom. Debt securities. Access exclusive markets data when you subscribe to the FT.

You can access current holdings, dividend information and update personal information, e. At OncoSil Medical we have a policy of continuous disclosure. We keep shareholders informed through ASX announcements, the company website, regular newsletters and our annual report.

Morningstar Investment Conference for Individual Investors. Connectivity services. Price to Sales Ratio vs Fair Ratio. Analyst Forecast: Insufficient data to show price forecast. It does not store any personal data. Show more Companies link Companies. Douglas Cubbin Non-Executive Chairman. All markets data located on FT. Open 0. Morningstar Investment Conference for Financial Professionals. Retirement strategies.